Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination for patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Through complementary initiatives with Viz.ai and the American Heart Association, Alnylam is advancing a comprehensive, system‑level approach to address persistent challenges of underdiagnosis and fragmented care in ATTR‑CM.

ATTR‑CM is a rapidly progressive, life‑threatening cause of heart failure that remains significantly underrecognized. Early and accurate diagnosis is critical to enabling access to appropriate management and improving outcomes. Despite advances in treatment, many patients remain undiagnosed for years, preventing access to necessary care. Alnylam aims to move ATTR-CM diagnosis upstream, accelerating earlier identification and enabling health systems to deliver consistent, high‑quality patient care at scale.